Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)
CNY 2.95
(4.24%)
CNY 2.95
(4.24%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 6.82 Billion CNY | 74.17% |
| 2022 | 3.91 Billion CNY | -8.22% |
| 2021 | 4.26 Billion CNY | -55.17% |
| 2020 | 9.52 Billion CNY | 44.87% |
| 2019 | 6.57 Billion CNY | -13.71% |
| 2018 | 7.61 Billion CNY | 42.93% |
| 2017 | 5.33 Billion CNY | 177.26% |
| 2016 | 1.92 Billion CNY | 21.39% |
| 2015 | 1.58 Billion CNY | 24.44% |
| 2014 | 1.27 Billion CNY | 39.45% |
| 2013 | 912.71 Million CNY | 42.61% |
| 2012 | 640 Million CNY | 101.57% |
| 2011 | 317.5 Million CNY | 23.99% |
| 2010 | 256.06 Million CNY | 42.26% |
| 2009 | 180 Million CNY | 63.64% |
| 2008 | 110 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 5.08 Billion CNY | -25.48% |
| 2024 Q2 | 6.97 Billion CNY | 37.2% |
| 2024 Q3 | 7.75 Billion CNY | 11.12% |
| 2023 Q3 | 3.88 Billion CNY | -11.05% |
| 2023 FY | 6.82 Billion CNY | 74.17% |
| 2023 Q4 | 6.82 Billion CNY | 75.62% |
| 2023 Q2 | 4.36 Billion CNY | -20.73% |
| 2023 Q1 | 5.51 Billion CNY | 40.66% |
| 2022 Q1 | 5.02 Billion CNY | 17.72% |
| 2022 FY | 3.91 Billion CNY | -8.22% |
| 2022 Q4 | 3.91 Billion CNY | -29.85% |
| 2022 Q3 | 5.58 Billion CNY | -3.49% |
| 2022 Q2 | 5.78 Billion CNY | 15.15% |
| 2021 FY | 4.26 Billion CNY | -55.17% |
| 2021 Q4 | 4.26 Billion CNY | -39.34% |
| 2021 Q2 | 7.95 Billion CNY | -9.84% |
| 2021 Q3 | 7.03 Billion CNY | -11.59% |
| 2021 Q1 | 8.82 Billion CNY | -7.3% |
| 2020 Q3 | 6.33 Billion CNY | 0.25% |
| 2020 FY | 9.52 Billion CNY | 44.87% |
| 2020 Q1 | 7.56 Billion CNY | 15.09% |
| 2020 Q2 | 6.32 Billion CNY | -16.46% |
| 2020 Q4 | 9.52 Billion CNY | 50.3% |
| 2019 Q2 | 6.38 Billion CNY | 0.63% |
| 2019 Q4 | 6.57 Billion CNY | -5.51% |
| 2019 Q3 | 6.95 Billion CNY | 8.88% |
| 2019 FY | 6.57 Billion CNY | -13.71% |
| 2019 Q1 | 6.34 Billion CNY | -16.65% |
| 2018 Q4 | 7.61 Billion CNY | 23.88% |
| 2018 Q3 | 6.14 Billion CNY | -8.91% |
| 2018 Q2 | 6.75 Billion CNY | -12.63% |
| 2018 Q1 | 7.72 Billion CNY | 44.96% |
| 2018 FY | 7.61 Billion CNY | 42.93% |
| 2017 Q1 | 2.66 Billion CNY | 38.36% |
| 2017 Q3 | 4.06 Billion CNY | 10.43% |
| 2017 Q4 | 5.33 Billion CNY | 31.18% |
| 2017 FY | 5.33 Billion CNY | 177.26% |
| 2017 Q2 | 3.67 Billion CNY | 38.33% |
| 2016 Q1 | 1.87 Billion CNY | 18.45% |
| 2016 FY | 1.92 Billion CNY | 21.39% |
| 2016 Q4 | 1.92 Billion CNY | 9.26% |
| 2016 Q3 | 1.75 Billion CNY | -19.8% |
| 2016 Q2 | 2.19 Billion CNY | 16.96% |
| 2015 Q3 | 1.47 Billion CNY | 11.37% |
| 2015 FY | 1.58 Billion CNY | 24.44% |
| 2015 Q2 | 1.32 Billion CNY | 12.57% |
| 2015 Q4 | 1.58 Billion CNY | 7.45% |
| 2015 Q1 | 1.17 Billion CNY | -7.62% |
| 2014 Q3 | 1.05 Billion CNY | -0.99% |
| 2014 Q1 | 1.1 Billion CNY | 20.97% |
| 2014 FY | 1.27 Billion CNY | 39.45% |
| 2014 Q4 | 1.27 Billion CNY | 21.01% |
| 2014 Q2 | 1.06 Billion CNY | -3.79% |
| 2013 Q3 | 883.38 Million CNY | 23.57% |
| 2013 Q4 | 912.71 Million CNY | 3.32% |
| 2013 Q2 | 714.9 Million CNY | -11.92% |
| 2013 FY | 912.71 Million CNY | 42.61% |
| 2013 Q1 | 811.65 Million CNY | 26.82% |
| 2012 Q4 | 640 Million CNY | 6.67% |
| 2012 Q3 | 600 Million CNY | 13.49% |
| 2012 Q1 | 528.66 Million CNY | 66.51% |
| 2012 Q2 | 528.66 Million CNY | 0.0% |
| 2012 FY | 640 Million CNY | 101.57% |
| 2011 Q3 | 323.02 Million CNY | -21.72% |
| 2011 Q4 | 317.5 Million CNY | -1.71% |
| 2011 Q1 | 306.2 Million CNY | 19.58% |
| 2011 Q2 | 412.63 Million CNY | 34.76% |
| 2011 FY | 317.5 Million CNY | 23.99% |
| 2010 Q4 | 256.06 Million CNY | 0.0% |
| 2010 FY | 256.06 Million CNY | 42.26% |
| 2009 FY | 180 Million CNY | 63.64% |
| 2008 FY | 110 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 13.75 Billion CNY | 50.377% |
| Shenzhen Glory Medical Co.,Ltd. | 290.6 Million CNY | -2248.317% |